MOUNT OLIVE, N.J., Oct. 2, 2017 /PRNewswire/ — Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial.  The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the […]